| 2024-07-25 | -43.4% | legal | SEC EDGAR | DXCM 8-K: 2.02, 8.01 (SEC Filing) |
| 2022-10-27 | +16.0% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-10-30 | -13.8% | earnings | Seeking Alpha | DexCom, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-10-30 | -13.8% | earnings | Seeking Alpha | DexCom Non-GAAP EPS of $0.61 beats by $0.04, revenue of $1.21B beats by $30M |
| 2025-10-30 | -13.8% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-10-30 | -13.8% | earnings | Yahoo Finance | DexCom Inc (DXCM) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - Yahoo Finance |
| 2025-10-30 | -13.8% | news | The Motley Fool | Should You Buy DexCom Stock Before Oct. 31? - The Motley Fool |
| 2025-10-30 | -13.8% | earnings | StockStory | DexCom (NASDAQ:DXCM) Beats Q3 Sales Expectations But Stock Drops - StockStory |
| 2025-05-02 | +13.3% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2025-09-18 | -12.4% | news | Seeking Alpha | DexCom falls after short report from Hunterbrook |
| 2021-07-29 | +12.2% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-05-01 | +12.1% | legal | SEC EDGAR | DXCM 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-10-31 | -11.9% | earnings | Seeking Alpha | DexCom slips after earnings on margin trends, 2026 growth concerns |
| 2025-10-31 | -11.9% | earnings | Seeking Alpha | DexCom projects 15% revenue growth for 2025 while advancing type 2 diabetes market coverage |
| 2025-10-31 | -11.9% | earnings | Seeking Alpha | DexCom, Inc. (DXCM) Q3 2025 Earnings Call Transcript |
| 2025-10-31 | -11.9% | news | Yahoo Finance | Why DexCom (DXCM) Stock Is Falling Today - Yahoo Finance |
| 2025-10-31 | -11.9% | earnings | Seeking Alpha | DexCom slips after earnings on margin trends, 2026 growth concerns - Seeking Alpha |
| 2025-10-31 | -11.9% | earnings | Zacks Investment Research | DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised - Zacks Investment Research |
| 2021-10-28 | +10.4% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2024-04-25 | -10.4% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2021-04-29 | -9.3% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-07-30 | -9.1% | legal | SEC EDGAR | DXCM 8-K: 2.02, 5.02 (SEC Filing) |
| 2025-07-31 | -9.0% | earnings | Yahoo Finance | DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise - Yahoo Finance |
| 2025-09-19 | -9.0% | news | Seeking Alpha | DexCom extends drop to reach five-month low |
| 2025-09-19 | -9.0% | news | Yahoo Finance | Why DexCom (DXCM) Shares Are Trading Lower Today - Yahoo Finance |
| 2025-09-19 | -9.0% | news | Seeking Alpha | DexCom stock drops to reach five-month low (DXCM:NASDAQ) - Seeking Alpha |
| 2025-03-07 | -8.9% | legal | SEC EDGAR | DXCM 8-K: 7.01 and 8.01 (SEC Filing) |
| 2025-11-11 | +8.4% | news | Yahoo Finance | Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - Yahoo Finance |
| 2025-11-11 | +8.4% | news | PR Newswire | Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately - PR Newswire |
| 2025-11-11 | +8.4% | news | ChartMill | DexCom Inc (NASDAQ:DXCM) Embodies the Affordable Growth Investment Method - ChartMill |
| 2026-02-13 | +8.0% | earnings | Seeking Alpha | DexCom outlines 2026 revenue growth of 11%-13% with G7 15 Day rollout and international expansion |
| 2026-02-13 | +8.0% | earnings | Seeking Alpha | DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript |
| 2026-02-13 | +8.0% | news | Yahoo Finance | Why Is DexCom (DXCM) Stock Rocketing Higher Today - Yahoo Finance |
| 2026-02-13 | +8.0% | earnings | Yahoo Finance | DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth - Yahoo Finance |
| 2023-02-09 | +8.0% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2021-11-22 | -7.8% | legal | SEC EDGAR | DXCM 8-K: 8.01 and (SEC Filing) |
| 2023-10-26 | +7.5% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2023-10-26 | +7.5% | legal | SEC EDGAR | DXCM 8-K: 8.01 (SEC Filing) |
| 2025-11-07 | -7.1% | news | MarketWatch | DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch |
| 2022-07-28 | -7.1% | legal | SEC EDGAR | DXCM 8-K: 8.01 (SEC Filing) |
| 2022-07-28 | -7.1% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-03-10 | -6.3% | legal | SEC EDGAR | DXCM 8-K: 5.02 and 7.01 (SEC Filing) |
| 2025-11-06 | -6.2% | earnings | Yahoo Finance | We Like DexCom's (NASDAQ:DXCM) Earnings For More Than Just Statutory Profit - Yahoo Finance |
| 2025-11-03 | +6.1% | news | Yahoo Finance | DexCom (DXCM) Stock Is Up, What You Need To Know - Yahoo Finance |
| 2025-11-03 | +6.1% | news | TradingView | DexCom (DXCM) Stock Is Up, What You Need To Know - TradingView |
| 2023-04-27 | -5.7% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2024-02-08 | -5.5% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2021-12-17 | +5.4% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2025-02-13 | +5.1% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2023-01-09 | -4.9% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2026-04-10 | -4.8% | news | ChartMill | DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy - ChartMill |
| 2026-03-05 | -4.7% | news | Yahoo Finance | Is DexCom Stock Underperforming the Nasdaq? - Yahoo Finance |
| 2026-01-20 | +4.6% | news | ChartMill | DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern - ChartMill |
| 2026-04-14 | -4.5% | news | Yahoo Finance | Here's Why DexCom (DXCM) is a Strong Growth Stock - Yahoo Finance |
| 2026-01-08 | -4.5% | news | Finviz | DexCom (DXCM) Stock Trades Down, Here Is Why - Finviz |
| 2026-01-08 | -4.5% | news | TradingView | DexCom (DXCM) Stock Trades Down, Here Is Why - TradingView |
| 2026-03-27 | -4.3% | news | MarketWatch | DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch |
| 2026-01-12 | +4.3% | earnings | Seeking Alpha | Dexcom reports 13% rise in preliminary Q4 revenue, issues 2026 outlook |
| 2026-01-12 | +4.3% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | +4.3% | news | Seeking Alpha | DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha |
| 2026-01-16 | +4.3% | earnings | Yahoo Finance | DexCom Stock Declines Following Strong Preliminary Q4 Results - Yahoo Finance |
| 2026-02-12 | +4.2% | earnings | Seeking Alpha | DexCom Q4 results beat on both lines; 2026 revenue guidance includes consensus |
| 2026-02-12 | +4.2% | earnings | Seeking Alpha | DexCom, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-12 | +4.2% | earnings | Seeking Alpha | DexCom Non-GAAP EPS of $0.68 beats by $0.03, revenue of $1.26B beats by $10M |
| 2026-02-12 | +4.2% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2026-02-12 | +4.2% | earnings | ChartMill | Dexcom Inc (NASDAQ:DXCM) Beats Q4 Profit Estimates Despite Revenue Shortfall - ChartMill |
| 2025-09-10 | -4.2% | news | Seeking Alpha | DexCom, Inc. (DXCM) Presents At Baird Global Healthcare Conference 2025 Transcript |
| 2025-10-28 | -3.8% | news | Seeking Alpha | DexCom falls as Hunterbrook releases new short report |
| 2026-04-15 | -3.8% | earnings | MarketBeat | DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat |
| 2026-04-15 | -3.8% | news | Stock Titan | Michael Brown (DXCM) files Form 144 to sell 1,700 restricted shares - Stock Titan |
| 2026-04-15 | -3.8% | executive | Quiver Quantitative | DEXCOM INC ($DXCM) President & CEO 2025 Pay Revealed - Quiver Quantitative |
| 2026-04-15 | -3.8% | news | MarketWatch | DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch |
| 2025-06-25 | -3.7% | news | Yahoo Finance | Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance |
| 2025-11-02 | +3.6% | earnings | simplywall.st | Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st |
| 2025-05-09 | -3.5% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2025-05-09 | -3.5% | legal | SEC EDGAR | DXCM 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-03-16 | +3.5% | news | Seeking Alpha | Most oversold healthcare stocks above $10B on Wall Street amid Middle East disruptions |
| 2026-03-16 | +3.5% | news | Yahoo Finance | Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - Yahoo Finance |
| 2026-03-04 | -3.4% | news | Seeking Alpha | DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further |
| 2026-03-04 | -3.4% | news | Seeking Alpha | DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further (NASDAQ:DXCM) - Seeking Alpha |
| 2026-03-26 | -3.4% | news | Stock Titan | Vanguard (DXCM) amendment shows 0 shares after internal realignment - Stock Titan |
| 2024-01-08 | +3.3% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | -3.3% | news | Motley Fool | Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins |
| 2026-04-23 | -3.3% | news | GlobeNewswire | Global Automated Insulin Delivery System Market Size/Share Worth USD 2684 Million by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis) |
| 2026-03-10 | -3.2% | news | ChartMill | DexCom Inc (NASDAQ:DXCM): A Prime Example of Growth at a Reasonable Price - ChartMill |
| 2026-03-10 | -3.2% | legal | openPR.com | Investigation announced for Long-Term Investors in shares of DexCom, Inc. (NASDAQ: DXCM) - openPR.com |
| 2026-03-10 | -3.2% | news | Stock Titan | Dexcom G7 study: weight benefits and fewer ketoacidosis hospital visits - Stock Titan |
| 2026-04-09 | -3.2% | news | PR Newswire | Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire |
| 2021-10-14 | -3.1% | legal | SEC EDGAR | DXCM 8-K: 1.01 and 2.03 (SEC Filing) |
| 2022-07-08 | -3.0% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2025-10-27 | -3.0% | legal | SEC EDGAR | DXCM 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-02-11 | -3.0% | earnings | Seeking Alpha | DexCom Q4 2025 Earnings Preview |
| 2026-02-11 | -3.0% | analyst | Yahoo Finance | What Are Wall Street Analysts' Target Price for DexCom Stock? - Yahoo Finance |
| 2026-01-09 | +2.9% | analyst | GuruFocus | DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus |
| 2026-04-16 | +2.5% | analyst | Motley Fool | 2 Healthcare Stocks That Could Outperform the Market Over the Next Decade |
| 2026-04-16 | +2.5% | news | TradingView | Here's Why You Should Add DexCom Stock to Your Portfolio Now - TradingView |
| 2026-04-16 | +2.5% | news | Stock Titan | Dexcom (DXCM) EVP sells 1,700 shares, still holds 111,204 - Stock Titan |
| 2022-02-10 | -2.4% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2022-08-05 | +2.4% | legal | SEC EDGAR | DXCM 8-K: 8.01 (SEC Filing) |
| 2023-08-28 | -2.3% | legal | SEC EDGAR | DXCM 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-04-21 | -2.2% | news | Exec Edge | Study Supports GlucoTrack’s Blood Glucose Monitoring Implant |
| 2026-04-21 | -2.2% | news | Simply Wall St. | A Look At Dexcom (DXCM) Valuation As Shares Lag And Fair Value Estimates Point Higher |
| 2026-04-21 | -2.2% | news | GuruFocus | State Street Premier Growth Equity V.I.S. Fund's DexCom Inc(DXCM) Holding History - GuruFocus |
| 2026-01-30 | -2.2% | earnings | Yahoo Finance | Q4 Preliminary Figures and 2026 Guidance Make DexCom (DXCM) Look Attractive - Yahoo Finance |
| 2025-10-16 | +1.9% | news | Yahoo Finance | Here’s Why Artisan Mid Cap Fund Exited Dexcom (DXCM) - Yahoo Finance |
| 2025-10-22 | +1.8% | news | Yahoo Finance | DexCom, Inc. (DXCM): A Bear Case Theory - Yahoo Finance |
| 2021-09-14 | +1.8% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2026-01-07 | -1.8% | executive | Stock Titan | Dexcom’s new chief backs longer‑lasting sensors and health‑tracking apps - Stock Titan |
| 2025-10-01 | -1.7% | news | Yahoo Finance | DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025 - Yahoo Finance |
| 2026-02-24 | -1.7% | earnings | Finviz | Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat - Finviz |
| 2025-12-13 | -1.7% | news | Insider Monkey | Jim Cramer on DexCom: “It’s Too Rich a Stock” - Insider Monkey |
| 2025-12-08 | +1.7% | news | GlobeNewswire | DEXCOM, INC. (NASDAQ: DXCM) SHAREHOLDER ALERT Bernstein - GlobeNewswire |
| 2026-03-18 | +1.6% | executive | Stock Titan | Dexcom (DXCM) legal chief sells 1,700 shares in 10b5-1 trade - Stock Titan |
| 2025-12-02 | +1.6% | analyst | Seeking Alpha | DexCom upgraded at Morgan Stanley on sorting out operational issues |
| 2025-01-13 | +1.5% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-10-06 | -1.5% | news | Seeking Alpha | DexCom May Be The Most Underrated Growth Story In Healthcare |
| 2025-10-06 | -1.5% | news | Seeking Alpha | DexCom May Be The Most Underrated Growth Story In Healthcare (NASDAQ:DXCM) - Seeking Alpha |
| 2026-04-07 | +1.5% | earnings | MarketBeat | Rathbones Group PLC Sells 18,632 Shares of DexCom, Inc. $DXCM - MarketBeat |
| 2026-02-25 | +1.5% | news | Stock Titan | How to watch Dexcom’s Raymond James investor conference update - Stock Titan |
| 2024-12-23 | -1.5% | legal | SEC EDGAR | DXCM 8-K: 1.01 (SEC Filing) |
| 2026-02-26 | +1.4% | legal | SEC EDGAR | DXCM 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-02-26 | +1.4% | news | Yahoo Finance | Aristotle Growth Equity Fund Bets on DexCom (DXCM) Due to Its Expanding CGM Market Leadership - Yahoo Finance |
| 2026-02-26 | +1.4% | news | Stock Titan | Android, Pixel and Fitbit leader Rick Osterloh joins Dexcom board - Stock Titan |
| 2025-12-16 | +1.4% | news | Seeking Alpha | 4 Reasons Why DexCom Could Be A Good Buy For 2026 |
| 2025-12-16 | +1.4% | news | Seeking Alpha | 4 Reasons Why DexCom Could Be A Good Buy For 2026 (NASDAQ:DXCM) - Seeking Alpha |
| 2025-09-16 | +1.4% | executive | Seeking Alpha | DexCom CEO takes medical leave |
| 2025-09-16 | +1.4% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2025-09-16 | +1.4% | news | Yahoo Finance | Wall Street is Bullish on DexCom (DXCM), Here’s Why - Yahoo Finance |
| 2025-11-20 | +1.4% | legal | Yahoo Finance | DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - Yahoo Finance |
| 2025-10-02 | +1.4% | earnings | Seeking Alpha | INCY and ABBV lead S&P 500 healthcare gainers in Q3; MOH and ALGN lag |
| 2025-09-17 | -1.3% | news | Yahoo Finance | DexCom, Inc. (DXCM): A Bull Case Theory - Yahoo Finance |
| 2026-04-20 | -1.3% | news | Motley Fool | Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom |
| 2026-04-20 | -1.3% | analyst | DirectorsTalk Interviews | DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A 35.78% Potential Upside - DirectorsTalk Interviews |
| 2022-01-10 | +1.3% | legal | SEC EDGAR | DXCM 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-09-28 | -1.2% | analyst | Yahoo Finance | UBS Downplays G7 CGM Sensor Concerns, Affirms DexCom’s Inc. (DXCM) ‘Buy’ Rating - Yahoo Finance |
| 2026-01-14 | -1.2% | earnings | Yahoo Finance | DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 - Yahoo Finance |
| 2026-04-19 | +1.2% | earnings | Barchart | DexCom’s Quarterly Earnings Preview: What You Need to Know |
| 2026-04-18 | +1.2% | earnings | MarketBeat | Chicago Capital LLC Reduces Position in DexCom, Inc. $DXCM - MarketBeat |
| 2026-04-18 | +1.2% | earnings | MarketBeat | DexCom, Inc. $DXCM Shares Purchased by Assetmark Inc. - MarketBeat |
| 2026-04-18 | +1.2% | earnings | MarketBeat | DexCom, Inc. $DXCM Shares Purchased by Moran Wealth Management LLC - MarketBeat |
| 2025-07-09 | +1.1% | news | Barron's | DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. - Barron's |
| 2026-03-24 | +1.1% | analyst | MarketWatch | DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch |
| 2024-10-24 | +1.1% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2026-01-13 | -1.1% | news | Seeking Alpha | DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-13 | -1.1% | news | Seeking Alpha | DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2025-12-19 | +1.1% | news | ChartMill | DexCom Inc (NASDAQ:DXCM): A High-Growth Stock Forming a Bullish Technical Setup - ChartMill |
| 2021-09-13 | -1.0% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2026-01-04 | +1.0% | news | Yahoo Finance | DexCom, Inc.'s (NASDAQ:DXCM) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance |
| 2023-07-27 | +1.0% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2025-11-27 | +1.0% | earnings | Yahoo Finance | Here’s Why Dexcom (DXCM) Traded Down in Q3 - Yahoo Finance |
| 2025-05-13 | +0.9% | legal | SEC EDGAR | DXCM 8-K: 5.02 and (SEC Filing) |
| 2026-04-08 | +0.9% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is DexCom (DXCM) Stock priced for growth | Price at $65.67, Up 4.05% - Stock Entry Points - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-11-13 | -0.9% | news | Yahoo Finance | DexCom Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance |
| 2025-12-18 | -0.9% | earnings | Yahoo Finance | DexCom (DXCM) Fell Due to Modest Guidance - Yahoo Finance |
| 2022-08-31 | +0.9% | legal | SEC EDGAR | DXCM 8-K: 5.02 (SEC Filing) |
| 2023-05-02 | +0.9% | legal | SEC EDGAR | DXCM 8-K: 8.01 and (SEC Filing) |
| 2025-12-03 | +0.8% | news | FinancialContent | Is DexCom Stock Underperforming the S&P 500? - FinancialContent |
| 2025-12-03 | +0.8% | news | Barchart | Is DexCom Stock Underperforming the S&P 500? - Barchart |
| 2023-05-03 | +0.8% | legal | SEC EDGAR | DXCM 8-K: 8.01 and (SEC Filing) |
| 2026-04-02 | +0.8% | news | Seeking Alpha | Nasdaq rebounds to end flat as chip, AI-related stocks recover after Trump's speech |
| 2026-04-02 | +0.8% | news | Stock Titan | Dexcom to post first-quarter results after the close on April 30 - Stock Titan |
| 2026-04-02 | +0.8% | earnings | MarketBeat | Compagnie Lombard Odier SCmA Grows Holdings in DexCom, Inc. $DXCM - MarketBeat |
| 2025-10-25 | -0.8% | analyst | TIKR.com | DexCom Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com |
| 2023-11-02 | +0.7% | legal | SEC EDGAR | DXCM 8-K: 8.01 (SEC Filing) |
| 2025-12-05 | +0.7% | news | ChartMill | DexCom Inc (NASDAQ:DXCM) Emerges as a Top Affordable Growth Stock - ChartMill |
| 2025-08-30 | -0.6% | analyst | Yahoo Finance | Argus Initiates Coverage of DexCom (DXCM) with a Buy Rating - Yahoo Finance |
| 2026-03-25 | +0.5% | news | ChartMill | DexCom Inc (NASDAQ:DXCM) Presents a Growth Stock Breakout Opportunity - ChartMill |
| 2026-03-25 | +0.5% | news | Yahoo Finance | Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance |
| 2023-05-05 | +0.5% | legal | SEC EDGAR | DXCM 8-K: 1.01, 2.03, 3.02, 8.01 (SEC Filing) |
| 2026-04-22 | -0.5% | news | GuruFocus | A Look at DexCom Inc (DXCM) After 3.1% Decline -- GF Value $109. - GuruFocus |
| 2026-04-22 | -0.5% | news | Cổng thông tin điện tử tỉnh Lào Cai | DexCom Inc. (DXCM) - Valuation Disparity Widens Amid Short-Term Price Weakness And Long-Term Growth Catalysts - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-12-15 | -0.5% | legal | Seeking Alpha | FDA making use of real-world evidence in device applications easier |
| 2025-10-29 | -0.4% | earnings | Seeking Alpha | DexCom Q3 2025 Earnings Preview |
| 2026-01-27 | -0.4% | analyst | Yahoo Finance | Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments - Yahoo Finance |
| 2026-03-02 | +0.3% | news | Seeking Alpha | DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript |
| 2026-03-02 | +0.3% | legal | SEC EDGAR | DXCM 8-K: 5.02 and (SEC Filing) |
| 2026-03-02 | +0.3% | news | Stock Titan | Kevin Sayer returns as Dexcom (NASDAQ: DXCM) executive chairman - Stock Titan |
| 2025-12-17 | -0.3% | news | Yahoo Finance | Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - Yahoo Finance |
| 2023-05-19 | +0.3% | legal | SEC EDGAR | DXCM 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-02-23 | +0.3% | news | Finviz | DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership - Finviz |
| 2025-10-13 | +0.3% | analyst | DirectorsTalk Interviews | DexCom, Inc. (DXCM) Stock Analysis: A 53% Upside Potential With Strong Buy Ratings - DirectorsTalk Interviews |
| 2021-07-01 | -0.2% | legal | SEC EDGAR | DXCM 8-K: 8.01 (SEC Filing) |
| 2022-04-28 | +0.2% | legal | SEC EDGAR | DXCM 8-K: 2.02 and (SEC Filing) |
| 2026-01-25 | +0.2% | news | Seeking Alpha | Notable healthcare headlines for the week: J&J, Moderna, Bristol Myers in focus |
| 2025-12-22 | +0.1% | legal | SEC EDGAR | DXCM 8-K: 5.02 and (SEC Filing) |
| 2025-12-22 | +0.1% | analyst | Yahoo Finance | Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential - Yahoo Finance |
| 2026-02-19 | -0.1% | earnings | simplywall.st | The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business - simplywall.st |
| 2024-02-15 | +0.1% | legal | SEC EDGAR | DXCM 8-K: 1.01, 1.02, 3.02 (SEC Filing) |
| 2026-04-26 | — | news | Insider Monkey | Is DexCom, Inc. (DXCM) A Good Stock To Buy Now? |
| 2026-04-26 | — | news | Yahoo Finance | Is DexCom, Inc. (DXCM) A Good Stock To Buy Now? - Yahoo Finance |
| 2026-04-26 | — | news | Insider Monkey | Is DexCom, Inc. (DXCM) A Good Stock To Buy Now? - Insider Monkey |
| 2026-04-24 | — | news | StockStory | 1 Cash-Producing Stock to Target This Week and 2 Facing Challenges |
| 2026-04-24 | — | earnings | Zacks | Will DXCM's G7 Uptake Continue to Drive Top-line Growth in Q1? |
| 2026-04-24 | — | news | ChartMill | DEXCOM INC (NASDAQ:DXCM) Shows Strong Fundamentals and a Promising Technical Breakout Setup - ChartMill |
| 2026-04-24 | — | earnings | TradingView | Will DXCM's G7 Uptake Continue to Drive Top-line Growth in Q1? - TradingView |